← Back to Directory

NovaBridge Biosciences (NBP) - Latest Market Data

Track the most recent price, market cap, volume, and performance data for NovaBridge Biosciences (NBP).

Get it on Google Play Download on Google Play Download on the App Store Download on the App Store

Equity Details

Price & Market Data

Price: $1.77

Daily Change: -$0.01 / 0.56%

Daily Range: $1.76 - $1.82

Market Cap: $204,697,856

Daily Volume: 801,030

Performance Metrics

1 Week: -5.26%

1 Month: -30.77%

3 Months: -44.79%

6 Months: -56.73%

1 Year: 92.12%

YTD: -57.04%

About NovaBridge Biosciences (NBP)

Analyze the market position of NovaBridge Biosciences (NBP). With a current price of 1.77, the stock exhibits a -$0.01 / 0.56% daily trend. A market capitalization of 204,697,856 indicates its scale. Discover its performance over 1-month (-30.77%) and 3-month (-44.79%) periods.

Company Details

Employees: 30

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.

Selected stocks

Mustang Bio, Inc. (MBIO)

National CineMedia, Inc. (NCMI)

Enel Chile S.A. (ENIC)

Inhibikase Therapeutics, Inc. (IKT)

Wetour Robotics Limited (WETO)